Help us transform the future of biologic drug delivery
Led by a respected, experienced team and headquartered in Glasgow, UK, Nebu~Flow has built momentum through high-value pharma collaborations and prestigious awards. With five patent families secured, prototype devices validated and active engagement with patients, carers and healthcare providers, we’re making fast progress towards our goal of bringing our next-generation nebuliser to market. We’re looking to raise our next investment round, so please get in touch if you’d like to know more.

Progress to date
The market
Primary target: Inflammation
8-10% CAGR
‘To and through the lung’:
Vaccines
Oligonucleotides
RNAs
T-Cell targets
Peptides
mAbs
No-type 2 (T2) mechanisms
ILD 6
Large growing markets
Market strategy
Target customers
Biopharma companies developing inhalable biologics
Clinical-stage innovators seeking better delivery platforms
Venture portfolios with high-potential biological assets
Respiratory service sector
Opportunities
Service fees from partnerships
Licensing of IPR
Milestones and royalties
Device sales
Inhalation data monetisation
Backed by brilliant life science investors:
Industry recognition
Nebu~Flow’s leadership team and advisory board are experts in pharma, technology and finance, with deep knowledge in respiratory drug delivery, acoustic technology and developing successful businesses. The company been featured at leading drug delivery and respiratory innovation forums, and has won a number of prestigious science and business awards, including CPHI Global Start-Up of the Year (2024)








